Richard Goldberg, M.D. is Emeritus Professor who served as the Laurence S. and Jean J. DeLynn Chair of Oncology and the Director of the Cancer Center at West Virginia University. During his tenure at West Virginia University Dr. Goldberg oversaw the clinical, research, and teaching missions of the cancer institute and its component organizations that include satellite clinical and clinical research locations that are dispersed throughout West Virgina. Dr. Goldberg ran the “N9741” Phase 3 trial that provided the data that led to the FDA approval of oxaliplatin for the treatment of patients with metastatic colorectal cancer (with a team from Sanofi). He serves in leadership roles for medical societies, including the Lower GI Committee of the American Joint Commission on Cancer, the patient advocacy group Fight Colorectal Cancer, and as a member/ad hoc advisor for ASCO and the U.S. Department of Defense Cancer program. He has published more than 397 papers in peer-reviewed journals and has been the author of 26 book chapters. His clinical interests are in the management of patients with malignancies in the gastrointestinal tract.
Dr. Goldberg is a graduate of Harvard University and received his medical degree from the State University Upstate Medical University.